RespireRx Pharmaceuticals Inc (fka RSPI)

[bladerunner1717]

gfp,

One of the more confusing (for me) aspects of the PR is this statement from Stoll: "It is fortunate that the Company had the foresight to initiate the three-month toxicology trials early this summer, so that we can have further information from these studies available before year end 2006."

Why is Stoll trumpeting his "foresight." Weren't the three-month toxicology studies required by the FDA in order to get the clinical hold lifted? Or is Stoll referring to the fact that he had the "foresight" to initiate the studies so quickly?

I hope these questions are cleared up on the CC.


Bladerunner